NCT05516979View on ClinicalTrials.gov

A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

September 26, 2022

Primary Completion Date

July 20, 2023

Study Completion Date

July 20, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

100 mg AP1189

AP1189 tablets for oral use

DRUG

Placebo

Matching placebo for oral use

Trial Locations (1)

Unknown

Timofei Mosneaga Republican Clinical Hospital, Chisinau

All Listed Sponsors
collaborator

NBCD A/S

INDUSTRY

lead

SynAct Pharma Aps

INDUSTRY